URGN FY 2023 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M+28.5% YoY

Gross Profit

$73M88.7% margin

Operating Income

-$66M-79.2% margin

Net Income

-$102M-123.6% margin

EPS (Diluted)

$-3.55

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$77M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$178M

Total Liabilities

$244M

Stockholders' Equity

-$65M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$64M	+28.5%
Gross Profit	$73M	$57M	+29.4%
Operating Income	-$66M	-$79M	+17.1%
Net Income	-$102M	-$110M	+6.9%